Retension Pharmaceuticals names Pavan Cheruvu to board of directors
RTSN•
RTSN•Retension Pharmaceuticals added Pavan Cheruvu to its board and named Alison D. Schecter chief medical officer, Alex Schwartz chief financial officer, and LeAnne Bloedon executive vice president of clinical development and operations. The company also formed a five-member Scientific Advisory Board.
Retension Pharmaceuticals added Pavan Cheruvu to its board; he is CEO of Amanat Acquisition and formerly led Bitterroot Bio. Alison D. Schecter became chief medical officer, Alex Schwartz joined as chief financial officer, and LeAnne Bloedon became executive vice president of clinical development and operations.
The company formed a Scientific Advisory Board comprising five investigators in hypertension, cardiology and nephrology. Schecter previously oversaw three hypertension registration trials at Mineralys Therapeutics; Schwartz led financial planning and investor relations at Ventyx Biosciences, and Bloedon previously served as head of development at Esperion Therapeutics.